Articles Related to Lung cancer
Predictive Value of ERCC1 Expression on Treatment Response to Cisplatin-Based Regimens in Small Cell Lung Cancer: A Retrospective Analysis
We aimed to determine whether the excision repair cross-complementation group 1 (ERCC1) expression predicts response to cisplatin-based chemotherapy in patients with small cell lung cancer (SCLC). This was a retrospective study, in which hospital files of 31 patients (29 males, 2 females; mean age, 62.26±7.71 years) were reviewed. All patients were treated with etoposide+cisplatin. The lung biopsy and mediastinal lymph node samples were applied anti-human monoclonal antibodies against ERCC1: immunohistochemical staining was considered positive if 25-100% of the cells showed nuclear staining, and negative if less than 25% of the cells showed negative or slight staining. Response to treatment was evaluated as regression (complete or partial response), progressive disease, or stable disease. Of the patients, 18 (58.1%) had limited-stage, and 13 (41.9%) had extensive-stage SCLC. Median follow-up duration was 15 months (range: 1-60 months). ERCC1 staining was positive in 9 of 31 patients (29.0%). In 12 patients (38.7%), tumor regression (complete or partial response) was obtained after chemotherapy. Tumor regression rate was higher in ERCC1 positive patients than those with negative ERCC1 expression (66.7% vs. 27.3%, p=0.036). In conclusion, high expression of ERCC1 was associated with higher response rate to cisplatin-based regimens in patients with SCLC.
microRNA 181a-5p Reprogramed Glucose and Lipid Metabolism in Non- Small Cell Lung Cancer
microRNAs play critical roles in cancer metabolisms. miRNA-181a-5p is significantly down-regulated in non-small lung cancer tissue and mesenchymal like lung cancer cells. Epithelial-mesenchymal transition mechanisms and cancer metabolism are controlled by the same signaling pathway.
Cisplatin-Gemcitabine Related Cardiomyopathy in Non-Small Cell Lung Cancer NSCLC Patient: A Case Study
Gemcitabine is a pyrimidine analog and cisplatin is a platinum agent, they are usually combined to form a chemotherapeutic doublet used to treat different types of oncological cancers, including non-small cell lung cancer (NSCLC). Although these agents are not known to cause such events, few cases related to possible cardiotoxicity side effects have been reported ; including angina, chronic heart failure, arrhythmias, and cardiac ischemia. A 52-year-old African male presented with Stage IV lung adenocarcinoma metastatic
to the bone, pleura and lymph node, EGFR wild type. Patient has a history of hypertension, diabetes, and atrial fibrillation and on rate control medications. He was treated initially with cisplatin-gemcitabine, after which he developed cardiomyopathy.
Double Stroke and Double Malignancy: A Case Report
Stroke associated with malignancy is rapidly increasing. Lesion types mainly resemble cardio embolic multiple ischemic lesions. We present a rare stroke patient with both ischemic and hemorrhagic lesions simultaneously. The etiology of stroke was found to be due to lung cancer and essential thrombocytosis. Differential diagnosis in this case can help for further investigation of strokes with malignancy.
Overuse and Misuse of Adjuvant Chemotherapy for Stages I and II Non-Small Cell Lung Cancer Chemotherapy: Empirical Findings from a Privately Insured Population
Among persons with early stage non-small cell lung cancer (NSCLC) resected for cure, appropriate use of adjuvant chemotherapy is an important additional determinant of survival. Oncology quality improvement initiatives focus on reducing overuse, underuse, and misuse.
Molecular Mechanisms of Mismatch Repair Genes in Cancer – A Brief Review
The DNA mismatch repair (MMR) system is necessary for the maintenance of genomic stability. The MMR system promotes genomic
fidelity by repairing base-base mismatches, insertion-deletion loops (IDLs) and heterologies generated during DNA replication and recombination.
Editorial Board Members Related to Lung cancer
Mellar P. Davis
Professor
Case Comprehensive Cancer Center
Case Western Reserve University
United States
Case Comprehensive Cancer Center
Case Western Reserve University
United States